Oyler said BeOne believes the medicine’s clinical and real-world evidence supports its position as the leading BTK inhibitor. GAAP income from operations was CNY 325 million, while net income was CNY 237 million. The company increased its full-year revenue outlook by CNY 300 million to a range of CNY 6.6 billion to CNY 6.8 billion. BeOne expects gross margin to remain in the high-80% range and operating expenses to total CNY 4.8 billion to CNY 5 billion for the year. About BeOne Medicines (NASDAQ:ONC)BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide.